September 9th 2024
John V. Heymach, MD, PhD, discusses updated outcomes from the AEGEAN trial of perioperative durvalumab vs placebo in resectable non–small cell lung cancer.
June 25th 2024
John Heymach, MD, PhD, discusses perioperative durvalumab in patients with resectable non-small cell lung cancer.
April 16th 2023
John V. Heymach, MD, PhD, discusses findings the phase 3 AEGEAN trial in patients with resectable non–small cell lung cancer.
June 27th 2022
Expert oncologist John Heymach, MD, PhD, addresses the potential role of immunotherapy in concomitant KRAS/TP53-mutated NSCLC.
Insight on the potential role of immunotherapy in patients with NSCLC and concomitant KRAS/STK11 or KRAS/KEAP1 mutations.
June 20th 2022
John Heymach, MD, PhD, discusses the poor outcomes that have been observed with immunotherapy in patients with NSCLC and EGFR mutations or ALK rearrangements.
Expert perspectives on the prevalence of molecular profiling in NSCLC, and the unmet needs and barriers preventing the uptake of routine molecular testing.
June 13th 2022
A brief discussion on insufficient tissue results in molecular profiling for NSCLC and how this can be avoided or addressed via liquid biopsy.
Expert oncologist John Heymach, MD, PhD, provides comprehensive insight on testing strategies for actionable mutations in NSCLC.
March 31st 2021
John V. Heymach, MD, PhD, discusses the future of immunotherapy in patients with non–small cell lung cancer.
April 19th 2015
John Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, discusses a study on KRAS mutations in lung cancer, which led to the identification of three more KRAS subsets.